Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Health agency reports U.S. babies with Zika-related birth defects

A mosquito is seen under a microscope at the Greater Los Angeles County Vector Control District in Santa Fe Springs, California, U.S., May 18, 2016. Reuters/Lucy Nicholson Three babies have been born in the United States with birth defects linked to likely Zika virus infections in the mothers during pregnancy, along with three cases of […]

Read More »

Obama Administration Hits Medicare Payment Target Early

By Louise Radnofsky Louise Radnofsky The Wall Street Journal CANCEL Biography @louiseradnofsky Google+ March 3, 2016 4:25 p.m. ET 32 COMMENTS WASHINGTON—Obama administration officials said Thursday they were almost a year ahead of their target to change the way Medicare pays hundreds of billions of dollars to providers for treating older Americans. The Department of Health […]

Read More »

Michigan Mayor Calls for More Aid

The mayor of Flint, Mich., said Monday that federal aid the city is set to receive is just the tip of the iceberg of what will be needed to recover from lead contamination in its drinking water. President Barack Obama on Saturday declared a federal emergency in Michigan, freeing as much as $5 million in […]

Read More »

Mylan Begins Hostile Bid for Perrigo

Mylan NV on Monday officially took its takeover bid directly to shareholders of Perrigo Co. (PRGO 0.88 %) after the company’s board and management publicly rebuffed previous advances.   Mylan is offering $75 in cash and 2.3 shares of Mylan for each Perrigo share held, valued at about $187 based on Friday’s closing price. Perrigo’s shares […]

Read More »

Novartis Heart Drug Overpriced, Group Says

Novartis AG’s (NVS -1.46 %) new heart-failure treatment should cost about 17% less than what the company is charging in the U.S. because wide use of the drug would strain health-care budgets, a nonprofit research group said Friday. Entresto’s U.S. list price, also known as its wholesale acquisition cost, is $12.50 a day, or about […]

Read More »

Lannett to Acquire UCB’s Kremers Urban Unit

Lannett Company Inc. has agreed to buy UCB SA’s Kremers Urban Pharmaceuticals Inc. for $1.23 billion. The deal, with tax benefits expected to top $100 million, also calls for potential contingency payments under sales and timing thresholds. Lannett said it expects the deal to close in the fourth quarter. Lannett’s shares, up 15% this year, […]

Read More »

Lilly Lung-Cancer Drug Stirs Price Debate

An experimental Eli Lilly (LLY 3.26 %) & Co. lung-cancer drug hasn’t reached the market, but some doctors are already arguing its price should be below average because the drug extended patient lives by only six to seven weeks in a clinical trial.   The pre-emptive price proposal—published on Thursday by the medical journal JAMA […]

Read More »

Lilly Says Court Ruled in its Favor on Patent

Eli Lilly & Co. said a federal court ruled that generic products proposed by a Teva Pharmaceutical Industries Ltd. TEVA -0.43 % unit would infringe a U.S. patent for the drug maker’s blockbuster cancer drug Alimta. A Teva spokesman said “we are disappointed with the district court’s decision and we are evaluating our options to […]

Read More »

FDA Grants Priority Review to Sarepta Drug

U.S. health regulators granted priority review status for Sarepta Therapeutics Inc. SRPT -0.91 % ’s treatment of a rare genetic disorder. Sarepta is developing eteplirsen to treat Duchenne muscular dystrophy, a condition that destroys muscles and frequently kills patients by their 30s. The disease affects roughly one in every 3,500 boys world-wide. The Food and […]

Read More »

Acorda Therapeutics Shares Surge

A U.S. patent review board on Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held by pharmaceutical companies and profiting from declines in their stock prices. The U.S. Patent and Trademark Office’s review board ruled against Mr. Bass’s challenge of […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom